Lucy Therapeutics Appoints Kim Drapkin as Board Chair
| LENZ Stock | 27.99 1.67 6.34% |
Slightly above 71 percent of all LENZ Therapeutics' investors are curious in acquiring. The analysis of the overall investor sentiment regarding LENZ Therapeutics suggests that a large number of traders are confidant. LENZ Therapeutics' investing sentiment can be driven by a variety of factors including economic data, LENZ Therapeutics' earnings reports, geopolitical events, and overall market trends.
LENZ |
WALTHAM, Mass., October 15, 2024--Lucy Therapeutics, Inc. , a biotech company developing proprietary small molecule therapies for complex neurological diseases including Rett syndrome, Parkinsons and Alzheimers, today announced the appointment of Kim Drapkin as Board Chair. She will help guide the strategic direction of LucyTx as the company enters its next phase of growth clinical trial development.
Read at finance.yahoo.com
 |
LENZ Therapeutics Fundamental Analysis
We analyze LENZ Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of LENZ Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of LENZ Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
LENZ Therapeutics is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
LENZ Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with LENZ Therapeutics stock to make a market-neutral strategy. Peer analysis of LENZ Therapeutics could also be used in its relative valuation, which is a method of valuing LENZ Therapeutics by comparing valuation metrics with similar companies.
Peers
LENZ Therapeutics Related Equities
| LPCN | Lipocine | 3.77 | ||||
| MRVI | Maravai Lifesciences | 2.96 | ||||
| HMY | Harmony Gold | 2.88 | ||||
| ARDX | Ardelyx | 0.17 | ||||
| PH | Parker Hannifin | 0.09 | ||||
| AMKR | Amkor Technology | 1.36 |
Additional Tools for LENZ Stock Analysis
When running LENZ Therapeutics' price analysis, check to measure LENZ Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LENZ Therapeutics is operating at the current time. Most of LENZ Therapeutics' value examination focuses on studying past and present price action to predict the probability of LENZ Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LENZ Therapeutics' price. Additionally, you may evaluate how the addition of LENZ Therapeutics to your portfolios can decrease your overall portfolio volatility.